OPDIVO QVANTIG

NDC 0003-6120 · E.R. Squibb & Sons, L.L.C.

Generic namenivolumab and hyaluronidase-nvhy

Dosage formINJECTION, SOLUTION

RouteSUBCUTANEOUS

Active ingredient(s)NIVOLUMAB, HYALURONIDASE (HUMAN RECOMBINANT)

Strength2000; 120 U/mL; mg/mL

Pharmacologic classEndoglycosidase [EPC], Glycoside Hydrolases [CS], Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA]

Marketing categoryBLA

Packages

0003-6120-01 — 1 VIAL, SINGLE-DOSE in 1 CARTON (0003-6120-01) / 5 mL in 1 VIAL, SINGLE-DOSE

Billed under HCPCS

J9289 — Injection, nivolumab, 2 mg and hyaluronidase-nvhy Medicare Part B payment limit (ASP + 6%): $28.14

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0003-3120 — nivolumab and hyaluronidase-nvhy, 0003-3734 — nivolumab, 0003-3756 — nivolumab, 0003-3772 — nivolumab, 0003-3774 — nivolumab, 0003-7125 — nivolumab and relatlimab-rmbw, 18657-117 — Hyaluronidase, 50242-077 — Trastuzumab and hyaluronidase-oysk, 50242-108 — rituximab and hyaluronidase, 50242-109 — rituximab and hyaluronidase, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-260 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-554 — ocrelizumab and hyaluronidase, 50242-933 — atezolizumab and hyaluronidase-tqjs, 51662-1555 — HYALURONIDASE, 57894-503 — daratumumab and hyaluronidase-fihj (human recombinant), 57894-510 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-514 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-515 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-522 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), +2 more

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.